JP2007530652A - 化学物質、調製方法、及び、新規結晶形態 - Google Patents

化学物質、調製方法、及び、新規結晶形態 Download PDF

Info

Publication number
JP2007530652A
JP2007530652A JP2007505632A JP2007505632A JP2007530652A JP 2007530652 A JP2007530652 A JP 2007530652A JP 2007505632 A JP2007505632 A JP 2007505632A JP 2007505632 A JP2007505632 A JP 2007505632A JP 2007530652 A JP2007530652 A JP 2007530652A
Authority
JP
Japan
Prior art keywords
monohydrochloride
crystalline
compound
hydroxy
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007505632A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007530652A5 (cg-RX-API-DMAC10.html
Inventor
ケイン,ダーレン,マイケル
パタノスター,イアン,レオナルド
シャプランド,ピーター,デイヴィッド,ペンバーシー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34963396&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2007530652(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0407521A external-priority patent/GB0407521D0/en
Priority claimed from GB0411688A external-priority patent/GB0411688D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2007530652A publication Critical patent/JP2007530652A/ja
Publication of JP2007530652A5 publication Critical patent/JP2007530652A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
JP2007505632A 2004-04-02 2005-03-30 化学物質、調製方法、及び、新規結晶形態 Pending JP2007530652A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0407521A GB0407521D0 (en) 2004-04-02 2004-04-02 Chemical process
GB0411688A GB0411688D0 (en) 2004-05-25 2004-05-25 Chemical process
US57446704P 2004-05-26 2004-05-26
PCT/GB2005/001241 WO2005095328A1 (en) 2004-04-02 2005-03-30 Chemical process and new crystalline form

Publications (2)

Publication Number Publication Date
JP2007530652A true JP2007530652A (ja) 2007-11-01
JP2007530652A5 JP2007530652A5 (cg-RX-API-DMAC10.html) 2008-03-21

Family

ID=34963396

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007505632A Pending JP2007530652A (ja) 2004-04-02 2005-03-30 化学物質、調製方法、及び、新規結晶形態

Country Status (14)

Country Link
US (1) US7846973B2 (cg-RX-API-DMAC10.html)
EP (1) EP1730104A1 (cg-RX-API-DMAC10.html)
JP (1) JP2007530652A (cg-RX-API-DMAC10.html)
KR (1) KR20070000508A (cg-RX-API-DMAC10.html)
AR (1) AR052301A1 (cg-RX-API-DMAC10.html)
AU (1) AU2005227733A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0509382A (cg-RX-API-DMAC10.html)
CA (1) CA2561400A1 (cg-RX-API-DMAC10.html)
IL (1) IL178064A0 (cg-RX-API-DMAC10.html)
MA (1) MA28558B1 (cg-RX-API-DMAC10.html)
NO (1) NO20064884L (cg-RX-API-DMAC10.html)
PE (1) PE20060678A1 (cg-RX-API-DMAC10.html)
TW (1) TW200536814A (cg-RX-API-DMAC10.html)
WO (1) WO2005095328A1 (cg-RX-API-DMAC10.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012032385A (ja) * 2010-06-29 2012-02-16 Japan Polypropylene Corp ポリオレフィンの結晶性分布分析方法およびその装置
JP2015528798A (ja) * 2012-07-06 2015-10-01 カルビスタ・ファーマシューティカルズ・リミテッド N−[(r)−1−[(s)−1−(4−アミノメチル−ベンジルカルバモイル)−2−フェニルエチルカルバモイル]−2−(4−エトキシ−フェニル)−エチル]−ベンズアミド塩酸塩の多形体
JP2016026158A (ja) * 2010-04-29 2016-02-12 ランドベック ファーマシューティカルズ イタリー エス.ピー.エー. 塩酸リトドリンの調製方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006066907A1 (en) * 2004-12-21 2006-06-29 Glaxo Group Limited Pharmaceutical formulations
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
JP5584138B2 (ja) 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
BR112013021638A2 (pt) 2011-02-25 2016-08-02 Irm Llc "compostos inibidores de trk, seu uso e composições que os compreendem"

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011416A1 (en) * 2002-07-26 2004-02-05 Theravance, Inc. CRYSTALLINE β2 ADRENERGIC RECEPTOR AGONIST
WO2004106279A2 (en) * 2003-05-27 2004-12-09 Theravance, Inc. CRYSTALLINE FORM OF β2 ADRENERGIC RECEPTOR AGONIST

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
US4353656A (en) * 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
EP0069715B1 (en) 1981-07-08 1986-11-05 Aktiebolaget Draco Powder inhalator
DK172541B1 (da) 1982-10-08 1998-12-07 Glaxo Group Ltd Apparat til administrering af medikamenter til patienter og en medikamentpakning til brug i apparatet
US4778054A (en) * 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
AU591152B2 (en) 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
FI944549L (fi) * 1992-04-02 1994-11-30 Smithkline Beecham Corp Allergisten ja tulehdussairauksien hoidossa käyttökelpoiset yhdisteet
US5495054A (en) * 1994-05-31 1996-02-27 Sepracor, Inc. Tetrahydroindeno[1,2-D][1,3,2]oxazaboroles and their use as enantioselective catalysts
US6040344A (en) * 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
GB9700226D0 (en) * 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
UA73965C2 (en) * 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
US6632666B2 (en) * 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
BR0314392A (pt) 2002-09-16 2005-07-12 Glaxo Group Ltd Composto ou um sal do mesmo, composição farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de uma doença inflamatória e/ou alérgica ou deficiência cognitiva em um mamìfero, e, combinação

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011416A1 (en) * 2002-07-26 2004-02-05 Theravance, Inc. CRYSTALLINE β2 ADRENERGIC RECEPTOR AGONIST
WO2004106279A2 (en) * 2003-05-27 2004-12-09 Theravance, Inc. CRYSTALLINE FORM OF β2 ADRENERGIC RECEPTOR AGONIST

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016026158A (ja) * 2010-04-29 2016-02-12 ランドベック ファーマシューティカルズ イタリー エス.ピー.エー. 塩酸リトドリンの調製方法
JP2012032385A (ja) * 2010-06-29 2012-02-16 Japan Polypropylene Corp ポリオレフィンの結晶性分布分析方法およびその装置
JP2015528798A (ja) * 2012-07-06 2015-10-01 カルビスタ・ファーマシューティカルズ・リミテッド N−[(r)−1−[(s)−1−(4−アミノメチル−ベンジルカルバモイル)−2−フェニルエチルカルバモイル]−2−(4−エトキシ−フェニル)−エチル]−ベンズアミド塩酸塩の多形体

Also Published As

Publication number Publication date
CA2561400A1 (en) 2005-10-13
WO2005095328A1 (en) 2005-10-13
BRPI0509382A (pt) 2007-09-18
IL178064A0 (en) 2006-12-31
EP1730104A1 (en) 2006-12-13
NO20064884L (no) 2006-10-26
MA28558B1 (fr) 2007-04-03
AR052301A1 (es) 2007-03-14
US7846973B2 (en) 2010-12-07
US20100063157A1 (en) 2010-03-11
TW200536814A (en) 2005-11-16
KR20070000508A (ko) 2007-01-02
PE20060678A1 (es) 2006-08-02
AU2005227733A1 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
CN100491342C (zh) 结晶β2肾上腺素能受体激动剂
CN100528835C (zh) 结晶形式的β2肾上腺素能受体激动剂
JP5041814B2 (ja) β2アドレナリン作用性レセプターアゴニストとしてのアリールアニリン誘導体
US7960551B2 (en) Compound
JP5807058B2 (ja) 二機能キノリン誘導体
KR20080094957A (ko) 아민 유도체
JP2006525372A (ja) アリールアニリンβ−2アドレナリン作用性レセプタアゴニストおよびコルチコステロイドの組み合わせ
JP2007505931A (ja) アミノ置換エチルアミノβ2アドレナリン作動性レセプターアゴニスト
US7846973B2 (en) Chemical process and new crystalline form
KR20060136478A (ko) 화학적 방법 및 결정형
US7772250B2 (en) Compounds
JP5468543B2 (ja) アセトアミド立体異性体
JP2010520188A (ja) カルモテロールの異性体を調製する方法
US20090227547A1 (en) Novel salt form of a Beta2-adrenergic agonist quinolin-2-one derivative
ZA200608096B (en) Chemical process and new crystalling form
MXPA06011239A (en) Chemical process and new crystalline form
HK1128681A (en) Amine derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110408

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120306

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120807